# Akso Health Group: Form 20-F for the period ended Mar 31, 2025

- Company: [Akso Health Group](/companies/ahg.md) (CIK 1702318)
- Form: 20-F
- Filed: 2025-08-14
- Accepted by EDGAR: Aug 14, 2025, 17:29 ET
- Period: 2025-03-31
- Accession: 0001213900-25-076862
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1702318/000121390025076862/ea0250582-20f_akso.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1702318/000121390025076862/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-04-01 to 2025-03-31 | $14.8m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2024-04-01 to 2025-03-31 | $15.1m | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2024-04-01 to 2025-03-31 | −$281.5k | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months, 2024-04-01 to 2025-03-31 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2024-04-01 to 2025-03-31 | −$166.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2024-04-01 to 2025-03-31 | −$30.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-04-01 to 2025-03-31 | −$135.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-04-01 to 2025-03-31 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-04-01 to 2025-03-31 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-04-01 to 2025-03-31 | 855,288,335 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-04-01 to 2025-03-31 | $1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-04-01 to 2025-03-31 | $154.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-03-31 | $176.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $196.1m | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $215.0m | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $13.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-03-31 | $15.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-03-31 | $199.1m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2025-03-31 | 1,655,583,530 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1702318/000121390025076862/ea0250582-20f_akso.htm

Filed Aug 14, 2025.
Source: SEC EDGAR, the filing index for accession 0001213900-25-076862. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.